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Abstract
Background: Seminomatous germ cell tumours (SGCT) are the most frequent ma-
lignancy in young men. Reliable prognostic biomarkers for the prediction of metas-
tasis at diagnosis and the risk of relapse in clinical stage I (CSI) are lacking. Adjuvant 
therapies carry a risk of overtreatment, whereas salvage therapies have a risk of high 
toxicities. Thus, the identification of reliable prognostic biomarkers is highly desirable 
to identify patients who will benefit from early adjuvant treatment. MicroRNAs (miR-
NAs) regulate tumour development and progression, and their potential as biomark-
ers has already been proven in a variety of malignancies.
Objectives: The aim of our study was to define a specific miRNA expression pattern 
that discriminates metastatic from non-metastatic primary SGCT.
Materials and methods: Total RNA was isolated from 24 formalin-fixed paraffin-
embedded (FFPE) primary SGCT tumours (10 non-metastatic, five metachronously 
and nine synchronously metastatic) and from 10 normal testicular tissue samples. 
Microarray analysis was performed for global miRNA expression profiling. The re-
sults were validated by quantitative real-time polymerase chain reaction (qRT-PCR). 
Statistical analysis was performed using SPSS.
Results: Microarray analyses revealed a specific miRNA pattern that distinguishes 
metastatic from non-metastatic SGCT. Sixty-three miRNAs were differentially ex-
pressed in metastatic compared to non-metastatic tumours (P < .01). Microarray re-
sults were confirmed by qRT-PCR for three out of five selected miRNAs (miR-29c-5p, 
miR-506-3p and miR-371a-5p; P < .05). All five miRNAs (miR-29c-5p, miR-506-3p, 
miR-1307-5p, miR-371a-5p and miR-371a-3p) showed differential expression be-
tween tumour and normal tissues (P < .05).
Conclusion: Metastatic primary SGCTs are characterized by a specific miRNA ex-
pression pattern. Therefore, specific miRNAs could represent a new tool to predict 
the metastatic potential in SGCT patients.
K E Y W O R D S
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1  | INTRODUC TION
Testicular cancer is the most frequent solid malignancy in young 
men, and pure seminoma (seminomatous germ cell tumour (SGCT)) 
is the most common histological subtype.1,2 According to current 
guidelines, surveillance is the option of choice for clinical stage I 
(CSI) SGCT patients.3 However, up to 20% have occult metastatic 
disease at the time of diagnosis and will relapse on a surveillance 
regimen.4 These patients are treated according to clinical stage at 
relapse, and cure rates close to 100% are reached. Nevertheless, 
significant acute and long-term toxicity remains an outcome for 
successful salvage treatment.5 Carboplatin chemotherapy and ra-
diation are adjuvant treatment options in CSI SGCT. Nevertheless, 
when applied in every patient, they result in an up to 80% risk of 
overtreatment. Tumour size and rete testis invasion have often 
been described as possible predictors of relapse. However, they 
have never been validated in a prospective setting, and their role 
as prognostic parameters remains doubtful.6,7 The detection of 
reliable prognostic biomarkers that accurately identify patients 
with CSI seminoma at risk of relapse would therefore be highly 
desirable.
MicroRNAs (miRNAs) are promising biomarkers in cancer re-
search. These small noncoding RNAs of approximately 20-25 base 
pairs in length regulate many cellular processes, such as cell devel-
opment, differentiation, apoptosis and proliferation.8 They play an 
important role in tumour development and progression.9 As miRNAs 
are stable, they are suitable biomarkers that can be analysed from 
several sources, such as formalin-fixed paraffin-embedded (FFPE) 
tissue samples and liquid biopsies.10 Recently, miRNAs of the miR-
371-73 cluster have been described as promising potential diag-
nostic and prognostic serum biomarkers in germ cell tumours.11-13 
Nevertheless, our knowledge concerning the role of miRNAs in germ 
cell tumour development and progression is still limited. The aim of 
our study was to define a specific prognostic miRNA expression pat-
tern in primary tumour tissue of SGCT that allows the differentiation 
between metastatic and non-metastatic SGCT.
2  | MATERIAL S AND METHODS
2.1 | Patient samples
FFPE tumour samples were obtained from 24 primary SGCTs. 
Samples were from 10 patients who did not show metastasis for 
at least 24 months after diagnosis under surveillance (non-meta-
static, median follow-up of 26 months [24-156]), five patients who 
presented with CSI at diagnosis and developed metachronous 
metastases under surveillance, and nine patients who presented 
with synchronous metastases. Staging was performed within four 
weeks after diagnosis. Surveillance protocols were used accord-
ing to European Association of Urology guidelines.3 In 10 patients, 
normal FFPE testicular tissue from tumour-distant areas was ob-
tained. All tissue samples were reviewed by a pathologist. Tumour 
classification was performed according to current TNM classifica-
tion systems.14
2.2 | Total RNA isolation
Total RNA was isolated from the FFPE samples using the miRNe-
asy FFPE Isolation Kit (Qiagen) according to the manufacturer's 
instructions. For determination of RNA quantity, a NanoDrop 
Spectrophotometer ND-1000 (Thermo Fisher) was used.
2.3 | MiRNA expression analyses
MiRNA expression analyses were performed using the human 
miRNA microarray technique (Agilent Technologies; Version 16). 
Total RNA (100 ng) was labelled and hybridized on a miRNA microar-
ray (miRNA complete labelling and hybridization kit, Agilent human 
microarrays; Agilent Technologies) according to the manufacturer's 
instructions. After extraction of raw data using Feature Extraction 
(Agilent Technologies), the data were analysed using Qlucore 
(Qlucore; Version 3). The total gene signal was normalized to the 
75th percentile of signal intensity.
2.4 | Quantitative real-time polymerase 
chain reaction
Quantitative qRT-PCR was performed on 100ng/µl total RNA using 
the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies), 
and specific TaqMan primers for miR-29c-5p, miR-371a-3p, miR-
1307-5p and RNU48 and TaqMan Gene expression Master Mix (Life 
Technologies) were used according to the manufacturer's protocol. 
Since no specific TaqMan primers were available for miR-371a-5p 
and miR-506-3p, qRT-PCR for these miRNAs was performed using 
the miRcury LNA miRNA PCR kit (Qiagen) according to the manu-
facturer's instructions (total RNA used: 50 ng/µL). In both methods, 
qRT-PCR was performed in triplicate, and the average value was cal-
culated. For used primers and probes, see Table S1. The expression 
values of tissue samples were normalized using RNU48 (TaqMan) or 
SNORD48 (miRcury LNA).
2.5 | Statistical analyses
For the miRNA expression analysis, we compared non-metastatic, 
metachronously and synchronously metastatic patients. For our 
further analysis, we compared non-metastatic to metastatic SGCT. 
Clinicopathological data were analysed using the chi-square test 
for categorical data and the Mann-Whitney U test for non-para-
metric data. Microarray data were analysed using Student's t test. 
Unpaired (two-group comparison) unsupervised hierarchical cluster-
ing was performed using Qlucore software. The parameters were 
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set to fold change (FC)> 1.5, P < .05 or < 0.01, respectively, and 
variance σ = 0.2. The false discovery rate (FDR) was defined using 
the Benjamini-Hochberg method for multiple testing, and q was 
adjusted at < 0.25 based on FDR. qRT-PCR data were analysed 
using REST 2009 (Technical University Munich, Germany & Qiagen, 
Version 2009) software and the Mann-Whitney U test. For the vali-
dation with qRT-PCR, we chose the respective miRNAs on the basis 
of low p-values, large fold changes, few outliers, a well-balanced 




Patient number, n (%) 10 (42) 5 (21) 9 (37)
Clinical stage at primary diagnosis, n (%)
CS I 10 (100) 5 (100)
IA 9 (90) 3 (60)
IB 1 (10) 2 (40)




CS III 1 (10)
IIIA 1 (11)
IIIB 0 (0)
Age at diagnosis (y)
Median [IQR] 38 [34.0-41.8] 39 [36.5-43.0] 46 [38.0-49.5]
β-HCG preoperative (Norm: <2.0 mIU/mL)
Median [IQR] 0.8 [0.1-10.9] 0.6 [0.2-1.2] 10.4 [1.2-25.3]
AFP preoperative (Norm: <5.8 IU/mL)
Median [IQR] 2.4 [1.6-2.9] 3.2 [1.7-7.3] 1.9 [1.2-2.2]
LDH preoperative (Norm: 0.0-262.0 U/L)
Median [IQR] 188.0 [165.8-242.0] 290.5 [228.0-362.0] 360.0 
[328.5-742.0]
S Stage
S0 10 (100) 5 (100) 8 (89)
S1 0 (0) 0 (0) 1 (11)
S2 0 (0) 0 (0) 0 (0)
S3 0 (0) 0 (0) 0 (0)
pT-Stadium, n (%)
pT1 9 (90) 3 (60) 5 (56)
pT2 1 (10) 2 (40) 4 (44)
pT3 0 (0) 0 (0) 0 (0)
pT4 0 (0) 0 (0) 0 (0)
Invasion of rete testis, n (%)
No 7 (70) 4 (80) 3 (33)
Yes 3 (30) 1 (20) 6 (67)
Tumour size (cm)
Median [IQR] 2.0 [1.7-3.1] 3.0 [3.0-5.8] 5.6 [4.3-7.8]
Death, n (%) 0 (0) 0 (0) 2 (22)
Relapses, n (%) - 5 (21) -
Time to relapse (mo)
Median [IQR] - 12 [9-17] -
Abbreviations: AFP, alpha-fetoprotein; IQR, interquartile range; LDH, lactate dehydrogenase; β-HCG, beta-human chorionic gonadotropin.
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distribution between up- and downregulated miRNAs and biologi-
cal relevance. Fold changes were calculated using Qlucore (miRNA 
expression analyses) and REST 2009 (qRT-PCR) software. To analyse 
qRT-PCR data, Mann-Whitney U test and boxplot diagrams were 
generated with SPSS (SPSS 23; IBM).
3  | RESULTS
3.1 | Clinicopathological parameters
Clinicopathological data are summarized in Tables 1 and 2. In the 
five patients who relapsed in CSI (= metachronous metastases), the 
median tumour size was 3.0 cm [interquartile range (IQR): 3.0-5.8] 
(see Table 1). Only one patient showed rete testis invasion. In terms 
of potential prognostic clinicopathological parameters, only the 
median level of preoperative lactate dehydrogenase (LDH) and the 
median tumour size differed significantly between non-metastatic 
and metastatic tumours (LDH: 188.0 vs 350.0, P < .001; tumour size: 
2.0 vs 5.0, P = .001; see Table 2). Two patients with synchronous 
metastases (clinical stage at diagnosis IIB and IIC) died. One patient 
died of bleomycin-induced pulmonary fibrosis, and the other died of 
generalized sepsis during chemotherapy.
3.2 | Microarray analysis
We identified 176 (P < .05) and 63 (P < .01) miRNAs that were dif-
ferentially expressed in metastatic compared to non-metastatic 
SGCT (Figure 1, Table 3). In the next step, we investigated syn-
chronously and metachronously metastatic tumours separately. 
398 miRNAs were expressed significantly different between non-
metastatic (n = 10) and synchronously (n = 9) metastatic SGCT 
(P < .05). Sixty-six miRNAs (P < .05) showed significantly different 
expression between non-metastatic (n = 10) and metachronously 
metastatic (n = 5) tumours (Figure 1). Of those, 36 miRNAs distin-
guished both synchronously and metachronously metastatic SGCT 
from non-metastatic SGCT (Figure 2, P < .05). Thereof, 25 miRNAs 
showed increased expression, and 11 miRNAs showed decreased 
expression in metastatic compared to non-metastatic tumours. 
We identified 93 (P < .05) and 3 (P < .01) miRNAs (miR-22-5p, miR-
625-5p, miR-4252) that were differentially expressed between me-
tachronously (n = 5) and synchronously (n = 9) metastatic tumours 
(P < .05).
3.3 | Results of quantitative real-time PCR
Microarray results were validated in the same cohort using qRT-
PCR. As described in the material and methods part, we chose 
four miRNAs, that were either significantly down- (miR-29c-5p, 
miR-506-3p and miR-1307-5p) (Figure 3A,C,E; Table 3) or upregu-
lated (miR-371a-5p) in metastatic tumours (Figure 3G, Table 3). 
Because of its recently described promising role as a diagnostic 
serum biomarker for testicular cancer, miR-371a-3p was also 
included.13
We found significantly different expression of miR-29c-5p, miR-
506-3p and miR-371a-5p in metastatic compared to non-metastatic 
Non-metastatic Metastatic
P-value(n = 10) (n = 14)
Age at diagnosis (years)
Median [IQR] 38 [34.0-41.8] 42 [37.8-49.0] 0.235
β-HCG preoperative
(Norm: <2.0 mIU/mL)
Median [IQR] 0.8 [0.1-10.9] 1.6 [0.5-18.4] 0.312
AFP preoperative
(Norm: <5.8 IU/mL)
Median [IQR] 2.4 [1.6-2.9] 2.0 [1.6-2.8] 0.666
LDH preoperative
(Norm: 0.0-262.0 U/L)
Median [IQR] 188.0 [165.8-241.5] 350.0 [278.5-558.5] <0.001
Invasion of rete testis, n (%)
No 7 (70) 7 (50)
Yes 3 (30) 7 (50) 0.421
Tumour size (cm)
Median [IQR] 2.0 [1.7-3.1] 5.0 [3.0-6.5] 0.001
Abbreviations: AFP, alpha-fetoprotein; IQR, interquartile range; LDH, lactate dehydrogenase; 
β-HCG, beta-human chorionic gonadotropin.
TA B L E  2   Differences in 
clinicopathological data between non-
metastatic and metastatic tumours
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tumours by qRT-PCR, with miR-29c-5p and miR-506-3p being sig-
nificantly downregulated and miR-371a-5p being significantly 
upregulated in metastatic tumours (Figure 3B,D,H). There was no 
significant difference between synchronously and metachronously 
metastatic tumours (miR-29c-5p: P = .560, FC=−1.03; miR-506-3p: 
P = .800; FC=−1.03; miR-371a-5p: P = .620; FC = 1.07).
Furthermore, the expression levels of miR-29c-5p and miR-
506-3p were significantly lower in tumour tissue than normal testic-
ular tissue, whereas miR-371a-5p expression was significantly higher 
(Figure 3 B,D,H).
The expression of miR-1307-5p did not significantly differ 
between metastatic and non-metastatic tumours (Figure 3 F). 
However, we found a significantly different expression level be-
tween normal testicular tissue and tumour tissue, with the expres-
sion level being significantly higher only in non-metastatic tumours 
(Figure 3E-F).
We found no significantly different expression levels for miR-
371a-3p in metastatic compared to non-metastatic tumours 
(Figure 3I). There was a significantly higher expression level of miR-
371a-3p in both non-metastatic and metastatic tumour tissue com-
pared to normal testicular tissue (Figure 3I).
4  | DISCUSSION
The development of valid prognostic markers in early stage SGCT 
would allow a more precise identification of patients who relapse and 
thus offer possibilities for early adjuvant therapies. Consequently, 
the toxicity of relapse treatment could be avoided, and long-term 
toxicities in these young cancer patients could be reduced.5 Thus, 
far, clinicopathological parameters failed to predict tumour progres-
sion in early stage SGCT, and reliable prognostic parameters are still 
lacking.6,7 The promising role of miRNAs as potential biomarkers has 
already been shown for numerous tumour entities, including urologi-
cal carcinomas.10,15
To the best of our knowledge, our study was the first to develop 
a miRNA expression tool for the identification of patients at high 
risk of relapse in SGCT. Hereby, we confirm a potential role of miR-
NAs as prognostic biomarkers in SGCT. We found a panel of miRNAs 
that clearly discriminate between metastatic and non-metastatic 
SGCTs. We confirmed three of them, miR-29c-5p and miR-506-3p 
and miR-371a-5p, by qRT-PCR. Within these, we found no differ-
ence between synchronously and metachronously metastatic tu-
mours, suggesting a common role of these miRNAs in metastasis 
F I G U R E  1   The heat map shows the 63 miRNAs (P < .01) that are significantly different expressed in metastatic compared to non-
metastatic SGCT
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TA B L E  3   Overview of the results of the microarray assay of 
miRNAs that discriminated between metastatic and non-metastatic 
SGCT. On the basis of low P-values, large fold changes, few outliers, 
a well-balanced distribution between up- and downregulated 





hsa-miR-4449 <.001 0.109 1.828
hsa-miR-1307-5p <.001 0.146 0.481
hsa-miR-6815-3p <.001 0.181 2.040
hsa-miR-371a-5p <.001 0.181 1.573
hsa-miR-6829-5p <.001 0.181 1.660
hsa-miR-4293 <.001 0.181 2.324
hsa-miR-4520-3p <.001 0.181 1.931
hsa-miR-6824-5p <.001 0.181 1.968
hsa-miR-4423-3p <.001 0.181 2.177
hsa-miR-6747-5p .001 0.181 1.744
hsa-miR-567 .001 0.181 1.550
hsa-miR-6797-5p .001 0.181 1.832
hsa-miR-758-5p .001 0.181 1.769
hsa-miR-542-5p .001 0.181 0.454
hsa-miR-6859-5p .001 0.181 1.940
hsa-miR-3130-5p .001 0.181 0.588
hsa-miR-3926 .002 0.181 1.526
hsa-miR-3911 .002 0.181 1.899
hsa-miR-3922-5p .002 0.181 1.851
hsa-miR-451a .002 0.181 0.219
hsa-miR-5189-3p .002 0.181 1.962
hsa-miR-3121-3p .002 0.185 1.803
hsa-miR-431-5p .002 0.185 0.553
hsa-miR-4419a .002 0.185 1.745
hsa-miR-3153 .002 0.185 1.661
hsa-miR-409-5p .002 0.185 0.461
hsa-miR-7641 .002 0.185 0.521
hsa-miR-6867-5p .002 0.185 1.540
hsa-miR-921 .003 0.197 0.551
hsa-miR-7152-5p .003 0.223 1.684
hsa-miR-610 .004 0.277 1.540
hsa-miR-5689 .004 0.277 1.660
hsa-miR-652-5p .004 0.277 2.018
hsa-miR-7846-3p .004 0.277 1.615
hsa-miR-6865-5p .005 0.281 1.649
hsa-miR-1287-5p .005 0.281 0.504
hsa-miR-4251 .005 0.281 2.101
hsa-miR-4298 .005 0.281 1.714
hsa-miR-3658 .005 0.281 0.582
hsa-miR-3130-3p .006 0.281 2.152





hsa-miR-605-5p .006 0.281 1.770
hsa-miR-4259 .006 0.281 1.830
hsa-miR-6872-5p .006 0.281 1.563
hsa-miR-6124 .006 0.281 1.676
hsa-miR-4451 .006 0.281 1.547
hsa-miR-2114-3p .006 0.281 1.622
hsa-miR-4792 .006 0.281 0.553
hsa-miR-3141 .006 0.281 1.626
hsa-miR-4319 .007 0.288 1.689
hsa-miR-29b-1-5p .007 0.288 0.478
hsa-miR-144-3p .007 0.288 0.172
hsa-miR-4793-5p .007 0.288 1.795
hsa-miR-298 .007 0.289 0.649
hsa-miR-6753-5p .008 0.289 1.680
hsa-miR-508-3p .008 0.308 0.266
hsa-miR-6738-5p .009 0.308 1.614
hsa-miR-132-5p .009 0.308 0.542
hsa-miR-3202 .009 0.308 1.531
hsa-miR-6715b-3p .009 0.320 0.604
hsa-miR-3192-5p <.010 0.322 1.525
hsa-miR-4435 <.010 0.322 1.639
hsa-miR-409-3p <.010 0.322 0.386
hsa-miR-509-3-5p .011 0.329 0.382
hsa-miR-664b-5p .011 0.329 0.640
hsa-miR-4732-5p .011 0.329 1.632
hsa-miR-711 .011 0.329 1.544
hsa-miR-506-3p .012 0.329 0.324
hsa-miR-2276-3p .012 0.329 1.783
hsa-miR-128-2-5p .012 0.329 0.467
hsa-miR-6777-5p .012 0.329 1.617
hsa-miR-4646-5p .012 0.329 1.528
hsa-miR-1301-5p .013 0.329 1.595
hsa-miR-4743-5p .013 0.329 1.548
hsa-miR-1183 .013 0.329 1.536
hsa-miR-4801 .013 0.329 1.800
hsa-miR-138-1-3p .013 0.329 1.702
hsa-miR-302c-5p .013 0.329 1.676
hsa-miR-4296 .013 0.329 1.931
hsa-miR-4738-3p .014 0.329 1.508
hsa-miR-1295b-3p .014 0.329 1.877
hsa-miR-1288-3p .014 0.329 0.625
hsa-miR-6862-5p .014 0.329 1.574
hsa-miR-2467-3p .015 0.329 1.547
hsa-miR-3197 .015 0.329 0.647
hsa-miR-508-5p .015 0.329 0.600
TA B L E  3   (Continued)
(Continues)




hsa-miR-6895-5p .015 0.329 1.551
hsa-let-7b-5p .015 0.333 0.479
hsa-miR-3173-3p .016 0.333 1.689
hsa-miR-204-5p .016 0.333 0.348
hsa-miR-6802-5p .016 0.333 1.705
hsa-miR-675-3p .016 0.333 1.795
hsa-miR-4518 .016 0.333 0.554
hsa-miR-99a-5p .016 0.333 0.357
hsa-miR-664a-5p .016 0.333 0.497
hsa-miR-411-5p .017 0.334 0.318
hsa-miR-4485-3p .017 0.336 0.537
hsa-miR-377-5p .017 0.336 0.560
hsa-let-7c-5p .018 0.337 0.429
hsa-miR-29c-5p .018 0.337 0.486
hsa-miR-1973 .018 0.341 0.565
hsa-miR-98-5p .019 0.346 0.396
hsa-miR-323a-3p .019 0.346 0.314
hsa-miR-378j .019 0.346 1.802
hsa-miR-4726-3p .019 0.347 1.720
hsa-miR-3925-5p .021 0.358 0.589
hsa-miR-6780b-5p .021 0.358 1.738
hsa-miR-542-3p .021 0.361 0.427
hsa-miR-892b .021 0.361 0.626
hsa-miR-8087 .021 0.361 1.551
hsa-let-7a-5p .022 0.362 0.479
hsa-miR-127-3p .022 0.362 0.396
hsa-miR-373-5p .022 0.362 1.607
hsa-miR-140-5p .023 0.378 0.575
hsa-miR-2392 .025 0.393 1.917
hsa-miR-379-5p .025 0.393 0.338
hsa-miR-513c-3p .025 0.393 0.577
hsa-miR-410-3p .025 0.393 0.359
hsa-miR-509-3p .026 0.393 0.376
hsa-miR-382-5p .026 0.393 0.375
hsa-miR-4638-5p .026 0.393 0.559
hsa-miR-507 .026 0.393 0.333
hsa-miR-6821-5p .027 0.393 1.664
hsa-miR-6749-3p .027 0.393 1.674
hsa-miR-424-5p .027 0.393 0.377
hsa-miR-487a-3p .027 0.393 0.384
hsa-miR-514a-3p .027 0.393 0.215
hsa-miR-6789-5p .028 0.401 1.782
hsa-miR-511-3p .030 0.410 0.475
hsa-miR-487b-3p .030 0.410 0.537
hsa-miR-7157-3p .030 0.410 0.659





hsa-miR-150-3p .030 0.410 1.526
hsa-miR-583 .030 0.410 1.661
hsa-miR-6804-3p .031 0.410 1.610
hsa-miR-10a-3p .031 0.410 0.612
hsa-miR-338-3p .031 0.410 0.458
hsa-miR-4286 .031 0.410 0.571
hsa-miR-10b-3p .032 0.410 0.617
hsa-miR-4327 .032 0.410 1.519
hsa-miR-432-5p .032 0.410 0.630
hsa-miR-135a-5p .032 0.410 0.423
hsa-let-7f-5p .032 0.410 0.497
hsa-let-7d-5p .033 0.410 0.507
hsa-miR-6781-5p .033 0.410 1.719
hsa-miR-6754-3p .033 0.410 1.764
hsa-miR-376b-3p .033 0.410 0.301
hsa-miR-299-5p .034 0.411 0.364
hsa-miR-493-5p .034 0.411 0.349
hsa-miR-154-5p .034 0.411 0.445
hsa-miR-136-3p .034 0.411 0.357
hsa-miR-503-5p .035 0.415 0.474
hsa-miR-10b-5p .036 0.415 0.460
hsa-miR-143-5p .036 0.415 0.505
hsa-miR-376a-5p .036 0.415 0.459
hsa-miR-4519 .036 0.415 2.027
hsa-miR-489-3p .036 0.415 0.636
hsa-miR-299-3p .037 0.418 0.350
hsa-miR-485-5p .037 0.419 0.637
hsa-miR-200a-5p .038 0.419 1.501
hsa-miR-758-3p .039 0.419 0.426
hsa-miR-455-5p .039 0.419 0.584
hsa-miR-497-5p .039 0.419 0.570
hsa-miR-4520-2-3p .040 0.428 0.665
hsa-miR-1180-3p .041 0.438 0.618
hsa-miR-195-5p .042 0.439 0.563
hsa-miR-21-3p .043 0.443 0.558
hsa-miR-369-5p .044 0.443 0.469
hsa-miR-6775-5p .044 0.443 1.552
hsa-miR-1248 .045 0.443 0.622
hsa-miR-144-5p .045 0.443 0.546
hsa-miR-1185-5p .045 0.443 0.565
hsa-miR-125b-5p .045 0.443 0.467
hsa-miR-376a-3p .047 0.451 0.395
hsa-miR-140-3p .047 0.451 0.664
hsa-miR-4315 .048 0.461 1.527
hsa-miR-6090 .049 0.464 1.637
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irrespective of the time of diagnosis. These results are consistent 
with the findings of others that report almost indistinguishable re-
sults for the transcriptional levels between synchronously and meta-
chronously metastatic SGCT.16,17 In summary, our results indicate 
that non-metastatic and metastatic SGCT can be distinguished by 
specific miRNA expression patterns.
Members of the miR-29 family have been identified as tu-
mour suppressors in a variety of malignancies.18 In gall blad-
der cancer, miR-29c-5p was significantly downregulated. Its 
overexpression in vitro led to repressed proliferation and to 
the induction of apoptosis by inhibition of the mitogen-acti-
vated protein kinases pathway.19 When evaluating the prog-
nostic value of miRNAs in seminomas by using next generation 
sequencing, Ruf et al identified 38 miRNAs that significantly 
distinguished non-metastatic from metastatic SGCT. A two-
miRNA combination (eg miR-29c + Enst00000387347; miR-
29a + Enst00000387347) was defined that discriminated 
metastatic from non-metastatic tumours.17 Consistent to our 
work miR-29c was expressed at significantly different levels in 
metastatic compared to non-metastatic tumours. Unfortunately, 
Ruf et al did not further describe if −3p or −5p was examined. 
Furthermore, they did not validate their results by qRT-PCR.17 
Additionally, to miR-29c and in contradiction to our work Ruf 
et al showed that miR-29a was significantly differentially ex-
pressed in metastatic compared to non-metastatic tumours. 
However, none of the other in our study identified miRNAs has 
been described by Ruf et al Our study results, together with the 
results of Ruf et al, suggest that miR-29c might be involved in 
the metastatic process of SGCTs.
We found that the expression level of miR-506-3p was lower in 
metastatic than non-metastatic tumours as well as in tumour tissue 
compared to normal testicular tissue. The role of the miR-506 fam-
ily and its pivotal role in regulating cell proliferation, differentiation, 
migration and invasion is well described.20 In the majority of tumour 
entities, this miRNA acts as a tumour suppressor, for example, in 
ovarian cancer or clear cell renal cell carcinoma.21,22 In respect of 
our study results, thus miR-506-3p might have a possible role as a 
tumour suppressor in SGCT.
We could not confirm a significant difference in miR-1307-5p 
expression in metastatic compared to non-metastatic tumours. 
However, we found a significantly higher expression of this miRNA 
in tumour tissue compared to normal testicular tissue. The func-
tion of miR-1307 is still unknown. Upregulation of miR-1307 plays a 
role in chemotherapy resistance of ovarian cancer cell lines. Death-
associated protein kinase 3 was identified as a target of miR-1307, 
which increases the antiapoptotic and survival abilities of tumour 
cells.23
Furthermore, we found that miR-371a-5p was significantly over-
expressed in metastatic compared to non-metastatic tumours. The 
results are similar to those in hepatocellular carcinoma, where miR-
371a-5p is upregulated and its overexpression is associated with 
poor survival.24
Another promising member of this cluster is miR-371a-3p, which 
was found to be overexpressed in the serum of testicular cancer 
patients compared to controls.11 Dieckmann et al recently demon-
strated that serum levels correlate with disease stage and response 
to treatment. Again, they postulate its role as an important prog-
nostic parameter and tumour marker that can be easily analysed 
from liquid biopsies.12,13 In terms of SGCT, only 15%-20% of patients 
express serum beta-HCG, displaying an important lack of efficacy 
of the classic tumour markers. In contrast, miR-371a-3p is generally 
detectable in the serum of SGCT patients.12,13 Interestingly, when 
examining miR-371a-3p in the primary tumour tissues of our study 
cohort, we did not find a difference between non-metastatic and 
metastatic tumours. This finding is in line with the results reported 
by Dieckmann et al that also failed to prove a difference concern-
ing primary tumour tissue.11 Nonetheless, we found a significant 
difference between tumour tissue and normal testicular tissue for 
both miR-371a-3p and miR-371a-5p. MiR-371a-5p belongs to the 
miR-371-73 cluster that was first described by Palmer et al to be 
overexpressed in germ cell tumours. Palmer et al hypothesized that 
several members of this cluster might serve as diagnostic biomarkers 
for testicular cancer.25
In addition, miR-302 and miR-367 clusters have been identi-
fied as putative serum markers, too.26 Nevertheless, miR-371a-3p 
proved to be the most sensitive and specific miRNA serum marker.27 
We did not find different miRNA expression of miR-302 and miR-
367 clusters between non-metastatic and metastatic SGCT in pri-
mary SGCT tissues.
There are several studies that examined the expression of 
miRNAs in primary SGCT tissue compared to normal testicular tis-
sue using microarrays. Novotny et al found miR-9, miR-105, miR-
182 and miR-183 to be highly expressed in SGCT28 whereas Bing 
et al found miR-21, miR-221, miR-222, miR-372 and miR-373 to be 
upregulated in primary SGCT tissue.29 Nevertheless, both studies 
did not examine differences between non-metastatic and meta-
static SGCT. In our study, none of the before mentioned miRNAs 
were differentially expressed between metastatic and non-meta-
static SGCT.
F I G U R E  2   The Venn diagram shows the total number and the 
overlapping number (bold) of significantly differentially expressed 
miRNAs to discriminate non-metastatic from synchronously 
metastatic SGCT (red), non-metastatic from metachronously 
metastatic SGCT (bright green) and non-metastatic from metastatic 
SGCT (dark green)
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Examining the primary tumour tissue or the serum of tes-
ticular cancer patients offers different possibilities. FFPE tis-
sue from orchiectomy specimens is easy to access because it 
is already part of routine pathological examination. The analy-
sis of original tumour specimens offers important insights into 
the functional characteristics of the primary tumour, and its 
prognostic value has already been proven in a variety of gen-
itourinary cancers.10,30 Liquid biopsies, such as patient serum 
samples, allow the monitoring of biomarkers in a dynamic 
time-dependent manner, thus offering important information 
F I G U R E  3   The box plots illustrate the expression changes of miR-29c-5p (A, B), miR-506-3p (C, D), miR-1307-5p (E, F) and miR-371a-5p 
(G, H) in normal testicular tissue, non-metastatic and metastatic tumours based on the array data (green boxes) and the PCR analyses (blue 
boxes); for miRNA-371-3p (I) based only on the PCR data (blue boxes)
1696  |     ERNST ET al.
F I G U R E  3   (Continued)
     |  1697ERNST ET al.
about therapy success. The combination of the information 
from primary tumour tissue together with that of patient serum 
samples offers a unique opportunity to gain precise insight into 
the tumour biology and functionality of testicular germ cell 
cancer.
Regarding the prognostic value of clinicopathological param-
eters in our study, non-metastatic and metastatic SGCT only dif-
fered with respect to tumour size and the preoperative level of 
LDH. In addition to rete testis invasion, tumour size is considered 
a possible prognostic factor in SGCT. However, its significance 
as a prognostic marker remains controversial. In a recently pub-
lished systematic review, tumour size positively correlated with 
relapse in ten of the 14 included studies, whereas rete testis in-
vasion was associated with tumour relapse in only four of the 12 
included studies.6 In a review by Boormans et al, there was no 
sufficient evidence for both factors.7 These results emphasize 
the need for the identification of reliable prognostic parameters 
in SGCT.
This study has several limitations, most notably the small number 
of cases examined (n = 24). Additionally, molecular biological anal-
ysis for global screening, such as microarrays, does not allow for a 
high number of cases because these analyses are very expensive. 
Future multicentre studies should validate our promising results in a 
larger, independent cohort of patients together with the determina-
tion of sensitivity and specificity for a single miRNA or a combination 
of multiple miRNAs (miRNA profiles).
5  | CONCLUSIONS
We showed for the first time that miRNA expression analysis is 
a promising tool for the identification of patients at high risk of 
relapse. The specific miRNA expression patterns identified seem 
to define the individual metastatic risk of SGCTs in a more precise 
manner than presently possible. A more personalized risk strati-
fication based on miRNA expression could be helpful to reduce 
unnecessary adjuvant treatment strategies on one hand and the 
burden of acute and long-term toxicities of salvage treatments on 
the other hand.
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